Quality of life study for relapsed myeloma immunotherapy
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This study compares quality of life and treatment results in people with relapsed or refractory multiple myeloma who receive either newer or standard immunotherapy. It aims to understand how these treatments affect daily living and outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 19 years or older.
- You have been diagnosed with multiple myeloma.
- Your myeloma has come back or is not responding to treatment.
- You have already been treated with at least one proteasome inhibitor, one immunomodulatory drug, and one monoclonal antibody.
- You are scheduled to start a new immunotherapy within one month of screening.
- You agree to take part after learning about the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at using bispecific antibodies (a type of immune therapy) to help people with multiple myeloma who have relapsed or stopped responding to other treatments. It aims to better understand why some patients may not respond or relapse after this targeted therapy.
This trial tests a new drug called CM336 for people with multiple myeloma that has come back or stopped responding to at least two previous treatments. It aims to see if CM336 can help control the disease.
This study looks at how your immune system responds after you receive CAR-T cell therapy for multiple myeloma. The goal is to learn more about the treatment's effects and how well it works.
This study tests non-chemotherapy supports meant to improve quality of life and immune health for people with multiple myeloma (or related conditions). Depending on the group, it may involve activities, nutrition, and/or a medication like a beta blocker.
This trial tests a new type of immune cell therapy (called CAR T-cells) designed to treat advanced multiple myeloma that has not responded well to standard treatments. The study focuses on safety and how well your body tolerates this personalized cell therapy.
This trial tests a new type of cell therapy (CAR-T cells) that targets two proteins, BCMA and GPRC5D, on myeloma cells. It aims to see if it is safe and effective for people whose multiple myeloma has come back or stopped responding to at least three previous treatments.
Hear when a new Multiple Myeloma, Relapsed trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.